An early phase clinical trial (NCT03020017) in GBM involved evaluating the efficacy of utilising spherical nucleic acid gold nanoparticles composed of siRNAs targeting Bcl2l12 (NU-0129). This evidence concerns the gene BCL2L12 and glioblastoma.